GlassScriptPhysician profile
Nelson Benjers
NPI 1629069968
$8,535.77
in general payments reported to CMS, 2019-2025
28 companies · $368 in 2025
The $368 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,711 · 2020: $1,402 · 2021: $2,946 · 2022: $1,469 · 2024: $641 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,009.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $1,962.99 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $733.45 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $619.29 | 2019-2022 | |
| Pfizer INC. | $525.30 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $503.69 | 2019-2021 | |
| Abbott Laboratories | $476.99 | 2019-2022 | |
| Esperion Therapeutics, INC. | $467.01 | 2020-2022 | |
| Actelion Pharmaceuticals US, INC. | $323.27 | 2019-2024 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.83 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $291.95 | 2019-2024 | Eliquis |
| Sanofi-Aventis U.S. LLC | $273.35 | 2019-2022 | |
| Novo Nordisk INC | $271.13 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $256.15 | 2019-2024 | |
| Glaxosmithkline, LLC. | $197.98 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $192.91 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $181.62 | 2019-2022 | |
| Bridgebio Pharma, INC. | $142.05 | 2025 | Attruby |
| Boston Scientific Corporation | $125.00 | 2019 | |
| Arbor Pharmaceuticals, INC. | $112.54 | 2019-2021 | |
| Cvrx, INC. | $99.51 | 2025 | Barostim Neo System |
| Kowa Pharmaceuticals America, INC. | $98.84 | 2020-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $93.39 | 2024 | Arcalyst |
| Vanda Pharmaceuticals INC. | $90.80 | 2019-2022 | |
| Philips North America LLC | $63.94 | 2022 | |
| Medtronic Vascular, INC. | $52.64 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $32.49 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $25.98 | 2019 | |
| Eisai INC. | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nelson Benjers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.